Robert Cherill

THE ECZEMA AREA AND SEVERITY INDEX (EASI): ASSESSMENT OF RELIABILITY IN ATOPIC DERMATITIS

Abstract: Objective– To test the reliability of the eczema area and severity index (EASI) scoring system by assessing inter‐ and intra‐observer consistency. Design: Training of evaluators, application, and assessment over 2 consecutive days. Setting– An academic center. Patients– Twenty adults and children with atopic dermatitis (AD); cohort 1 (10 patients ≥8 years) and cohort 2 (10 patients <8 years). Interventions– None. Main outcome measure– The EASI was used by 15 dermatologist evaluators to assess atopic dermatitis in cohort 1 and cohort 2 on 2 consecutive days. Inter‐ and intraobserver reliability were analyzed. Results– Overall intra‐evaluator reliability of the EASI was in the fair‐to‐good range. Inter‐evaluator reliability analyses indicated that the evaluators assessed the patients consistently across both study days. Conclusions– This study demonstrated that the EASI can be learned quickly and utilized reliably in the assessment of severity and extent of AD. There was consistency among the evaluators between consecutive days of evaluation. These results support the use of the EASI in clinical trials of therapeutic agents for AD.

Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme.

Objectiveu2002 To validate the Eczema Area and Severity Index (EASI) by assessing its internal consistency, reliability and sensitivity to change and by correlating it to other efficacy parameters.